Centrexion Stock Faces Investor Concerns Amid Market Challenges Centrexion Therapeutics' stock hit a 52-week low of $0.77, reflecting a 31.68% annual decline. Despite its strong liquidity position, investor confidence remains shaken due to market volatility. Analysts, however, maintain optimistic price targets of $4 to $10, underscoring potential recovery despite current challenges in the chronic pain management sector.3